|
US5800815A
(en)
*
|
1903-05-05 |
1998-09-01 |
Cytel Corporation |
Antibodies to P-selectin and their uses
|
|
US5464778A
(en)
*
|
1989-03-08 |
1995-11-07 |
Board Of Regents Of The University Of Oklahoma |
Glycoprotein ligand for P-selectin and methods of use thereof
|
|
WO1991006632A1
(en)
*
|
1989-10-20 |
1991-05-16 |
New England Medical Center Hospitals, Inc. |
Inhibition of padgem-mediated cell binding
|
|
US6387884B1
(en)
|
1990-06-18 |
2002-05-14 |
Stanford University |
Leukocyte homing modulation
|
|
US6391857B1
(en)
|
1990-06-18 |
2002-05-21 |
Stanford University |
Methods and compositions for endothelial binding
|
|
NZ240316A
(en)
*
|
1990-10-25 |
1996-12-20 |
Univ Michigan |
Compound for treating disease mediated by the elaboration of elam-1 on endothelial cells
|
|
US6124267A
(en)
*
|
1991-02-05 |
2000-09-26 |
Southpac Trust Internationals, Inc. |
O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
|
|
US6309639B1
(en)
|
1991-02-05 |
2001-10-30 |
The Board Of Regents Of The University Of Oklahoma |
Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
|
|
US5807745A
(en)
*
|
1991-03-11 |
1998-09-15 |
New England Medical Center Hospitals, Inc. |
Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component
|
|
AU1926692A
(en)
*
|
1991-04-19 |
1992-11-17 |
Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for endothelial binding
|
|
US6121233A
(en)
*
|
1991-04-19 |
2000-09-19 |
John L. Magnani |
Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
|
|
WO1992019646A1
(en)
*
|
1991-05-03 |
1992-11-12 |
The Rockefeller University |
Analog of endothelial leukocyte adhesion molecule (elam)
|
|
AU2029392A
(en)
*
|
1991-05-14 |
1992-12-30 |
Board Of Regents Of The University Of Oklahoma, The |
Peptide inhibitors of inflammation
|
|
US5646123A
(en)
*
|
1991-06-10 |
1997-07-08 |
Alberta Research Council |
Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
|
|
JPH07507040A
(ja)
*
|
1991-09-10 |
1995-08-03 |
セントコー，インコーポレイテッド |
セレクチンによって介在される炎症のペプチド阻害剤
|
|
WO1993005803A1
(en)
*
|
1991-09-25 |
1993-04-01 |
Genetics Institute, Inc. |
Anti-inflammatory selectin inhibitors
|
|
AU3914393A
(en)
*
|
1991-12-18 |
1994-03-15 |
Board Of Regents Of The University Of Oklahoma, The |
Peptide inhibitors of inflammation mediated by selectins
|
|
ES2152251T3
(es)
*
|
1992-04-30 |
2001-02-01 |
Genentech Inc |
Variantes del dominio lectina de la selectina.
|
|
DE69332881T2
(de)
*
|
1992-05-05 |
2004-01-29 |
Aeres Biomedical Ltd |
Antikörper gegen p-selectin und ihre verwendung
|
|
US6033667A
(en)
*
|
1992-05-05 |
2000-03-07 |
Cytel Corporation |
Method for detecting the presence of P-selectin
|
|
US5728802A
(en)
*
|
1992-05-06 |
1998-03-17 |
Affymax Technologies N.V. |
Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
|
|
US5643873A
(en)
*
|
1992-05-06 |
1997-07-01 |
Affymax Technologies N.V. |
Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
|
|
US5648458A
(en)
*
|
1992-05-06 |
1997-07-15 |
Affymax Technologies N.V. |
Peptides and compounds that bind to ELAM-1
|
|
CA2136428A1
(en)
*
|
1992-05-28 |
1993-12-09 |
George A. Heavner |
Peptide inhibitors of selectin binding
|
|
CA2136844A1
(en)
*
|
1992-05-28 |
1993-12-09 |
George A. Heavner |
Peptide inhibitors of selectin binding
|
|
US5440015A
(en)
*
|
1992-07-21 |
1995-08-08 |
Glycomed Incorporated |
Selectin peptide medicaments for treating disease
|
|
US5753617A
(en)
*
|
1992-09-08 |
1998-05-19 |
Centocor, Inc. |
Peptide inhibitors of cellular adhesion
|
|
DE69331331T2
(de)
|
1992-10-02 |
2002-08-14 |
Alberta Research Council, Edmonton |
Entzündungshemmende tolerogene und immunoinhibitorische eigenschaften von karbohydrate bindende peptide
|
|
US6277975B1
(en)
|
1992-10-23 |
2001-08-21 |
Genetics Institute, Inc. |
Fusions of P-selectin ligand protein and polynucleotides encoding same
|
|
JPH08502886A
(ja)
*
|
1992-10-23 |
1996-04-02 |
ジェネティックス・インスティテュート・インコーポレイテッド |
新規ｐ−セレクチンリガンド蛋白質
|
|
US5843707A
(en)
*
|
1992-10-23 |
1998-12-01 |
Genetics Institute, Inc. |
Nucleic acid encoding a novel P-selectin ligand protein
|
|
EP0668907A1
(en)
*
|
1992-11-16 |
1995-08-30 |
Board Of Regents Of The University Of Oklahoma |
Glycoprotein ligand for p-selectin and methods of use thereof
|
|
WO1994014836A1
(en)
*
|
1992-12-18 |
1994-07-07 |
Centocor, Inc. |
Peptide inhibitors of selectin binding
|
|
US5976540A
(en)
*
|
1993-05-17 |
1999-11-02 |
T Cell Sciences, Inc. |
Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
|
|
WO1994026786A1
(en)
|
1993-05-17 |
1994-11-24 |
T Cell Sciences, Inc. |
Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
|
|
US5856300A
(en)
*
|
1994-05-12 |
1999-01-05 |
T Cell Sciences, Inc. |
Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
|
|
US5750508A
(en)
*
|
1993-06-16 |
1998-05-12 |
Glycomed Incorporated |
Sialic acid/fucose based medicaments
|
|
WO1995014787A1
(en)
*
|
1993-11-22 |
1995-06-01 |
Centocor, Inc. |
Peptide inhibitors of selecting binding
|
|
US5663151A
(en)
*
|
1994-03-04 |
1997-09-02 |
Bristol-Myers Squibb Company |
Sulfated α-glycolipid derivatives as cell adhesion inhibitors
|
|
CA2142153A1
(en)
*
|
1994-03-04 |
1995-09-05 |
Jacques Banville |
Sulfated .beta.-glycolipid derivatives as cell adhesion inhibitors
|
|
AU2361395A
(en)
*
|
1994-04-28 |
1995-11-29 |
Genetics Institute Inc. |
Novel P-selectin ligand protein
|
|
US5686426A
(en)
*
|
1994-11-17 |
1997-11-11 |
Bristol-Myers Squibb Company |
Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
|
|
CZ401497A3
(cs)
*
|
1995-06-14 |
1998-07-15 |
The General Hospital Corporation |
P-selektinové ligandy a příbuzné molekuly a způsoby
|
|
US5747463A
(en)
*
|
1995-11-13 |
1998-05-05 |
Bristol-Myers Squibb Company |
Malonate derivatives of glycolipids as cell adhesion inhibitors
|
|
WO1997047646A1
(en)
|
1996-06-10 |
1997-12-18 |
Boren Thomas |
Helicobacter pylori adhesin binding group antigen
|
|
DK1783222T3
(da)
|
1998-10-23 |
2012-07-09 |
Kirin Amgen Inc |
Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
JP5183010B2
(ja)
|
2002-05-16 |
2013-04-17 |
グリコミメティクス， インコーポレイテッド |
セレクチンによって媒介される機能を阻害するための化合物および方法
|
|
DE602004011272T2
(de)
|
2003-11-19 |
2008-12-24 |
Glycomimetics, Inc. |
Spezifischer antagonist sowohl für e- als auch p-selektine
|
|
JP2008505928A
(ja)
|
2004-07-08 |
2008-02-28 |
アムジェン インコーポレーテッド |
治療用ペプチド
|
|
WO2006036834A2
(en)
|
2004-09-24 |
2006-04-06 |
Amgen Inc. |
MODIFIED Fc MOLECULES
|
|
DK1928892T3
(da)
|
2005-08-09 |
2012-01-30 |
Glycomimetics Inc |
Glycomimetiske inhibitorer af PA-IL-lectin PA-IIL-lectin eller begge lectiner fra pseudomonas
|
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
PL1934236T3
(pl)
|
2005-09-02 |
2013-04-30 |
Glycomimetics Inc |
Heterobifunkcjonalne inhibitory pan-selektyny
|
|
US8895510B2
(en)
|
2008-04-08 |
2014-11-25 |
Glycomimetics, Inc. |
Pan-selectin inhibitor with enhanced pharmacokinetic activity
|
|
WO2012037034A1
(en)
|
2010-09-14 |
2012-03-22 |
Glycomimetics, Inc. |
E-selectin antagonists
|
|
WO2013096926A1
(en)
|
2011-12-22 |
2013-06-27 |
Glycomimetics, Inc. |
E-selectin antagonist compounds, compositions, and methods of use
|
|
PT2928476T
(pt)
|
2012-12-07 |
2018-05-10 |
Glycomimetics Inc |
Compostos, composições e métodos que utilizam antagonistas de e-selectina para mobilização de células hematopoiéticas
|
|
WO2016089872A1
(en)
|
2014-12-03 |
2016-06-09 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
|
|
US11045485B2
(en)
|
2016-01-22 |
2021-06-29 |
Glycomimetics, Inc. |
Glycomimetic inhibitors of PA-IL and PA-IIL lectins
|
|
US11291678B2
(en)
|
2016-03-02 |
2022-04-05 |
Glycomimetics, Inc |
Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
|
|
JP2019524791A
(ja)
|
2016-08-08 |
2019-09-05 |
グリコミメティクス， インコーポレイテッド |
Ｅ−セレクチンの阻害剤もしくはｃｘｃｒ４の阻害剤との、またはｅ−セレクチンおよびｃｘｃｒ４両方のヘテロ二機能性阻害剤とのｔ細胞チェックポイント阻害剤の組み合わせ
|
|
US11072625B2
(en)
|
2016-10-07 |
2021-07-27 |
Glycomimetics, Inc. |
Highly potent multimeric e-selectin antagonists
|
|
JP7244422B2
(ja)
|
2017-01-11 |
2023-03-22 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｐｓｇｌ－１アンタゴニスト及びその使用
|
|
SG11201907848YA
(en)
|
2017-03-14 |
2019-09-27 |
Five Prime Therapeutics Inc |
Antibodies binding to vista at acidic ph
|
|
CA3054605A1
(en)
|
2017-03-15 |
2018-09-20 |
Glycomimetics, Inc. |
Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
|
|
US11712446B2
(en)
|
2017-11-30 |
2023-08-01 |
Glycomimetics, Inc. |
Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
|
|
BR112020013198A2
(pt)
|
2017-12-29 |
2020-12-01 |
Glycomimetics, Inc. |
inibidores heterobifuncionais de e-selectina e galectina-3
|
|
KR20200128025A
(ko)
|
2018-03-05 |
2020-11-11 |
글리코미메틱스, 인크. |
급성 골수성 백혈병 및 관련 병태의 치료 방법
|
|
MX2020009786A
(es)
|
2018-03-21 |
2020-10-12 |
Five Prime Therapeutics Inc |
Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido.
|
|
US12091462B2
(en)
|
2018-07-11 |
2024-09-17 |
Five Prime Therapeutics, Inc. |
Antibodies binding to vista at acidic pH
|
|
WO2020139962A1
(en)
|
2018-12-27 |
2020-07-02 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of e-selectin and galectin-3
|
|
JP2023535332A
(ja)
*
|
2020-07-20 |
2023-08-17 |
インスメッド インコーポレイテッド |
好中球セリンプロテアーゼを抽出するおよびジペプチジルペプチダーゼ１媒介性病態を治療するための方法
|